greeksoup/ stock research
Stock research / United States / Funds / ARCH Venture Management, LLC

ARCH Venture Management, LLC

CIK 1274403 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

ARCH Venture Management, LLC reported 12 US-listed holdings worth $1.10 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Parabilis Medicines Inc. Com (16.0%), Beam Therapeutics Inc. (14.2%) and Rapport Therapeutics Inc. (14.1%). Against the quarter before, it opened 3 positions, added to 0, trimmed 1 and sold out of 1.

Reported holdings$1.10B+62.5% on Q1 2026
Positions12+2 on Q1 2026
The largest ten99.3%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedHeldTrimmed
PBLS16.0%BEAM14.2%RAPP14.1%SPTX12.4%ERAS11.8%VIR11.8%MAZE11.2%LYEL4.1%GENB3.0%TXG0.8%BOLD0.6%

The 12 largest of its 12 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $260.6 million in 9 positions$261MQ3 24Q4 2024: $230.2 million in 9 positions$230MQ4 24Q1 2025: $206.2 million in 9 positions$206MQ1 25Q2 2025: $299.1 million in 11 positions$299MQ2 25Q3 2025: $492.4 million in 9 positions$492MQ3 25Q4 2025: $651.7 million in 9 positions$652MQ4 25Q1 2026: $677.1 million in 10 positions$677MQ1 26Q2 2026: $1.10 billion in 12 positions$1.10BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 3Held 8Trimmed 1Sold out 1
Opened: 3Held: 8Trimmed: 1Sold out: 1

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 3

  1. Parabilis Medicines Inc. Com PBLS$175.5 million
  2. Seaport Therapeutics Inc. SPTX$136.6 million
  3. Boundless Bio Inc. BOLD$6.7 million

Trimmed 1

  1. Vir Biotechnology, Inc. VIR-222,500 shares · -2%

Sold out of 1

  1. Q32 Bio Inc. QTTB$2.1 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Parabilis Medicines Inc. Com PBLS6,412,780$175.5 million15.95%new
Beam Therapeutics Inc. BEAM4,540,132$155.8 million14.16%no change
Rapport Therapeutics Inc. RAPP3,728,738$155.4 million14.12%no change
Seaport Therapeutics Inc. SPTX6,294,951$136.6 million12.42%new
Erasca Inc. ERAS7,091,557$129.9 million11.81%no change
Vir Biotechnology, Inc. VIR12,694,163$129.4 million11.76%-222,500
Maze Therapeatics MAZE4,120,053$123.0 million11.18%no change
Lyell Immunopharma Inc. LYEL3,247,162$45.5 million4.14%no change
Generate Biomedicines Inc. GENB1,944,426$32.8 million2.98%no change
10X Genomics Inc. TXG217,834$8.4 million0.76%no change
Boundless Bio Inc. BOLD2,694,095$6.7 million0.61%new
Gossamer Bio Inc. GOSS8,055,916$1.3 million0.12%no change
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 1 it sold out of are in the box above.